摘要

【摘要】
目的 探讨氟伏沙明治疗伴轻度抑郁的帕金森患者的效果观察。

方法 选取2021年7月~2023年7月医院收治的82例帕金森伴轻度抑郁患者作为研究对象，依照随机数表法分为两组。对照组给予普拉克索联合理性情绪行为疗法，观察组在对照组基础上另给予氟伏沙明治疗。比较两组患者帕金森病量表（Unified-Parkinson Disease Rating Scale, UPDRS）评分、蒙特利尔认知评估量表（Montreal Cognitive Assessment, MoCA）评分、简易智能精神状态检查量评分（Mini-Mental State Examiniation, MMSE）、临床疗效、血清胰岛素样生长因子（Insulin-like Growth Factor 1, IGF-1）、胱抑素Ｃ（Cystatin C, Cys-C）水平及不良反应。

结果 治疗后，两组患者的UPDRS评分均降低（P<0.05），且观察组更低（P<0.05）；两组患者的MoCA和MMSE分值均升高（P<0.05），且观察组更高（P<0.05）。观察组总有效率高于对照组（P<0.05）。两组患者的IGF-1水平均上升（P<0.05），且观察组更高（P<0.05），两组患者的Cys-C水平均降低（P<0.05），且观察组更低（P<0.05）。两组不良反应发生率无差异性（P>0.05）。

结论 氟伏沙明用于帕金森伴轻度抑郁患者疗效显著，可改善血清学指标，降低认知障碍，安全可靠。

关键词：【关键词】氟伏沙明；帕金森；轻度抑郁

ABSTRACT

[Abstract]
Objective To investigate the effect of fluvoxamine in the treatment of Parkinson's disease with mild depression.

Methods A total of 82 patients with Parkinson's disease and mild depression admitted to the hospital from July 2021 to July 2023 were selected as research objects and were randomly divided into two groups. The control group was given pramipexole combined with rational emotive behavior therapy, and the observation group was also given fluvoxamine on the basis of the control group. Parkinson's Disease Scale (Unified-Parkinson Disease Rating Scale, UPDRS) score, Montreal Cognitive Assessment Scale (Montreal Cognitive Assessment, MoCA) score, simple mental status test score (Mini-Mental State Examiniation, MMSE), clinical efficacy, serum insulin-like growth factor (Insulin-like Growth Factor 1, IGF-1), cystatin C (Cystatin C, Cys-C) level and adverse reactions of two groups were compared.

Results After treatment, UPDRS scores decreased in both groups (P<0.05), and observation group was lower (P<0.05), MoCA and MMSE scores were increased in both groups (P<0.05), and higher in the observation group (P<0.05). After treatment, the total response rate of the observation group was higher (P<0.05). After treatment, IGF-1 levels increased in both groups (P<0.05), and higher in the observation group (P<0.05), Cys-C levels were decreased in both groups (P<0.05), and the observation group was lower (P<0.05). There was no difference in the incidence of adverse reactions in both groups (P>0.05).

Conclusion   Fluvoxamine is effective in patients with Parkinson's disease accompanied by mild depression. It can improve serological indexes, reduce cognitive impairment, and it demonstrates a favorable safety profile.

Key words: [Key words] Fluvoxamine; Parkinson's disease; Depression